Audentes Therapeutics, Inc.

May 16, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
8-K
0001564590-18-013716.nc
Current report Includes: Material events, Director, Executive officer elections resignations, departures, Financial disclosures, Changes in control, etc.
Item
8.01 Other: Important event
9.01 Financial Statements and Exhibits
Period of report
May 16, 2018
May 10, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
10-Q BOLD 
0001564590-18-012956.nc XBRL XML (6)
Quarterly report ( Financial statements and condition ) ( Risk ) ( Corporate Governance ) ( Executive compensation ) ( Management Discussion Analysis MDA MD&A )
Focus Period
2018 : Q1
Fiscal year ends
--12-31
Period of report
March 31, 2018
Financials (experimental)
In USD 3 mo ending 2018-03-31 3 mo ending 2017-03-31
Net Income  -25,571,000  -18,115,000
EPS Diluted  -0.74  -0.83
EPS Basic  -0.74  -0.83
May 9, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
8-K
0001564590-18-012421.nc
Current report Includes: Material events, Director, Executive officer elections resignations, departures, Financial disclosures, Changes in control, etc.
Item
2.02 Financial: Results of Operations and Financial Condition
9.01 Financial Statements and Exhibits
Period of report
May 9, 2018
May 8, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
8-K
0001193125-18-155291.nc
Current report Includes: Material events, Director, Executive officer elections resignations, departures, Financial disclosures, Changes in control, etc.
Item
5.02 Governance: Departure/Appointment/Compensation Directors and Officers
Period of report
May 8, 2018
May 8, 2018 .
Issuer
Audentes Therapeutics, Inc. BOLD
Reporting Owner
Holles Natalie C. [ Officer, President and COO, ]
Signed By
Thomas Soloway as attorney-in-fact for Natalie Holles
Preview. View filing ...
4
0001209191-18-028492.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
May 7, 2018
Stock Option (right to buy)
[A : Grant / award] 25,000 shares x $0.00/sh Total owned: 25,000 [ Underlying Securities: Common Stock ] 25,000 shares
April 27, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
DEFA14A
0001564590-18-009603.nc
Additional proxy soliciting materials - definitive - required under Section 14
April 27, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
DEF 14A
0001564590-18-009595.nc
Definitive proxy statements. Related to: Annual proxy shareholder meeting, Executive officer and director compensation, Voting
Period of report
June 8, 2018
April 23, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
CT ORDER
9999999997-18-005209.nc
Confidential Treatment Orders
April 4, 2018 .
Issuer
Audentes Therapeutics, Inc. BOLD
Reporting Owner
Patterson Matthew R [ Director, Officer, President & CEO, ]
Signed By
Thomas Soloway as attorney-in-fact for Matthew Patterson
Preview. View filing ...
4
0001209191-18-023956.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
April 2, 2018
Common Stock
[M : Exer. or conv. of deriv. security exempted] 700 shares x $0.78/sh Total owned: 700
Common Stock
[S : Open market or private sale] 700 shares x $30.0129/sh Total owned: 0
Common Stock
Total owned: 171,814 [ By Matthew R. Patterson Revocable Trust ]
Stock Option (right to buy)
[M : Exer. or conv. of deriv. security exempted] 700 shares x $0.00/sh Total owned: 199,050 [ Underlying Securities: Common Stock ] 700 shares
April 2, 2018 .
Issuer
Audentes Therapeutics, Inc. BOLD
Reporting Owner
NEWMAN MARY [ Officer, SVP, Regulatory Affairs, ]
Signed By
Thomas Soloway as attorney-in-fact for Mary Newman
Preview. View filing ...
4
0001209191-18-022600.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
March 15, 2018
Common Stock
[M : Exer. or conv. of deriv. security exempted] 4,076 shares x $2.19/sh Total owned: 4,076
Common Stock
[S : Open market or private sale] 4,076 shares x $29.6603/sh Total owned: 0
Common Stock
[M : Exer. or conv. of deriv. security exempted] 5,524 shares x $2.19/sh Total owned: 5,524
Common Stock
[S : Open market or private sale] 5,524 shares x $30.7902/sh Total owned: 0
Common Stock
[M : Exer. or conv. of deriv. security exempted] 400 shares x $2.19/sh Total owned: 400
Common Stock
[S : Open market or private sale] 400 shares x $31.617/sh Total owned: 0
Stock Option (right to buy)
[M : Exer. or conv. of deriv. security exempted] 10,000 shares x $0.00/sh Total owned: 23,817 [ Underlying Securities: Common Stock ] 10,000 shares
March 29, 2018 .
Issuer
Audentes Therapeutics, Inc. BOLD
Reporting Owner
PRASAD SUYASH [ Officer, Senior VP & Chief Med Officer, ]
Signed By
Thomas Soloway as attorney-in-fact for Suyash Prasad
Preview. View filing ...
4
0001209191-18-022169.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
March 29, 2018
Common Stock
[M : Exer. or conv. of deriv. security exempted] 7,800 shares x $0.79/sh Total owned: 7,800
Common Stock
[S : Open market or private sale] 7,800 shares x $30.025/sh Total owned: 0
Stock Option (right to buy)
[M : Exer. or conv. of deriv. security exempted] 7,800 shares x $0.00/sh Total owned: 70,870 [ Underlying Securities: Common Stock ] 7,800 shares
March 29, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
S-3ASR
0001193125-18-102103.nc
Automatic shelf registration statement of securities of well-known seasoned issuers
March 28, 2018 .
Issuer
Audentes Therapeutics, Inc. BOLD
Reporting Owner
PRASAD SUYASH [ Officer, Senior VP & Chief Med Officer, ]
Signed By
Thomas Soloway as attorney-in-fact for Suyash Prasad
Preview. View filing ...
4
0001209191-18-022004.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
March 26, 2018
Common Stock
[M : Exer. or conv. of deriv. security exempted] 1,900 shares x $0.79/sh Total owned: 1,900
Common Stock
[S : Open market or private sale] 1,900 shares x $30.00/sh Total owned: 0
Common Stock
[M : Exer. or conv. of deriv. security exempted] 300 shares x $0.79/sh Total owned: 300
Common Stock
[S : Open market or private sale] 300 shares x $30.00/sh Total owned: 0
Stock Option (right to buy)
[M : Exer. or conv. of deriv. security exempted] 1,900 shares x $0.00/sh Total owned: 78,970 [ Underlying Securities: Common Stock ] 1,900 shares
Stock Option (right to buy)
[M : Exer. or conv. of deriv. security exempted] 300 shares x $0.00/sh Total owned: 78,670 [ Underlying Securities: Common Stock ] 300 shares
March 28, 2018 .
Issuer
Audentes Therapeutics, Inc. BOLD
Reporting Owner
LANGE LOUIS G [ Director, ]
Signed By
Thomas Soloway as attorney-in-fact for Louis Lange MD PhD
Preview. View filing ...
4
0001209191-18-022003.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
March 26, 2018
Common Stock
[S : Open market or private sale] 11,568 shares x $29.00/sh Total owned: 414,231
Common Stock
[S : Open market or private sale] 6,700 shares x $29.57/sh Total owned: 407,531
Common Stock
[S : Open market or private sale] 1,732 shares x $29.95/sh Total owned: 405,799
Common Stock
[S : Open market or private sale] 500 shares x $28.284/sh Total owned: 10,055 [ By Adrienne M. MacMillan Revocable Trust ]
Common Stock
[S : Open market or private sale] 500 shares x $29.464/sh Total owned: 9,555 [ By Adrienne M. MacMillan Revocable Trust ]
Common Stock
[S : Open market or private sale] 600 shares x $28.38/sh Total owned: 21,078 [ By Amygdala Lange Trust ]
Common Stock
[S : Open market or private sale] 400 shares x $29.5725/sh Total owned: 20,678 [ By Amygdala Lange Trust ]
Common Stock
[S : Open market or private sale] 517 shares x $28.3206/sh Total owned: 4,041 [ By Lange Minor's Trust ]
Common Stock
[S : Open market or private sale] 483 shares x $29.5695/sh Total owned: 3,558 [ By Lange Minor's Trust ]
Common Stock
[S : Open market or private sale] 18,400 shares x $28.3514/sh Total owned: 68,943 [ By Asset Management Ventures Fund, L.P. ]
Common Stock
[S : Open market or private sale] 6,600 shares x $29.2655/sh Total owned: 62,343 [ By Asset Management Ventures Fund, L.P. ]
Preview. View filing ...
4
0000947871-18-000243.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
March 8, 2018
Common Stock
[S : Open market or private sale] 58,428 shares x $34.06/sh Total owned: 3,638,000 [ See Footnotes ]
Common Stock
[S : Open market or private sale] 21,300 shares x $34.67/sh Total owned: 3,616,700 [ See Footnotes ]
Common Stock
[S : Open market or private sale] 47,395 shares x $35.86/sh Total owned: 3,569,305 [ See Footnotes ]
Common Stock
[S : Open market or private sale] 11,305 shares x $36.44/sh Total owned: 3,558,000 [ See Footnotes ]
Common Stock
[S : Open market or private sale] 1,066 shares x $36.04/sh Total owned: 3,556,934 [ See Footnotes ]
Common Stock
[S : Open market or private sale] 16,937 shares x $34.92/sh Total owned: 3,539,997 [ See Footnotes ]
March 9, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
10-K BOLD 
0001564590-18-005154.nc XBRL XML (6)
Annual report ( Financial statements and condition ) ( Risk ) ( Corporate Governance ) ( Executive compensation ) ( Management Discussion Analysis MDA MD&A )
Focus Period
2017 : FY
Fiscal year ends
--12-31
Period of report
Dec. 31, 2017
Financials (experimental)
In USD 3 mo ending 2017-12-31 3 mo ending 2016-12-31 12 mo ending 2017-12-31 12 mo ending 2016-12-31 12 mo ending 2015-12-31
Net Income  -24,375,000  -19,676,000  -90,238,000  -59,668,000  -26,458,000
EPS Diluted  -0.82  -0.91  -3.40  -5.59  -23.03
EPS Basic  -0.82  -0.91  -3.40  -5.59  -23.03
March 8, 2018 .
Filer
Audentes Therapeutics, Inc.
Preview. View filing ...
8-K
0001564590-18-004941.nc
Current report Includes: Material events, Director, Executive officer elections resignations, departures, Financial disclosures, Changes in control, etc.
Item
2.02 Financial: Results of Operations and Financial Condition
9.01 Financial Statements and Exhibits
Period of report
March 8, 2018
Preview. View filing ...
4
0000947871-18-000219.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
March 2, 2018
Common Stock
[S : Open market or private sale] 386,080 shares x $35.06/sh Total owned: 3,743,558 [ See Footnotes ]
Common Stock
[S : Open market or private sale] 35,558 shares x $36.33/sh Total owned: 3,708,000 [ See Footnotes ]
Common Stock
[S : Open market or private sale] 200 shares x $36.06/sh Total owned: 3,707,800 [ See Footnotes ]
Common Stock
[S : Open market or private sale] 11,372 shares x $33.03/sh Total owned: 3,696,428 [ See Footnotes ]
Preview. View filing ...
SC 13G/A
0001144204-18-008583.nc
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and institutions
Preview. View filing ...
SC 13G/A
0001193805-18-000211.nc
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and institutions
db